Other
Total
Regeneron Pharmaceuticals Total decreased by 0.7% to $15.52B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 17.0%, from $13.26B to $15.52B. Over 5 years (FY 2020 to FY 2025), Total shows an upward trend with a 33.7% CAGR.
Analysis
StatementBalance Sheet Statement
SectionOther
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ4 2017
Last reportedQ1 2026Apr 29, 2026
How to read this metric
Changes reflect shifts in the cost basis of the investment portfolio due to purchasing or selling activity.
Detailed definition
The amortized cost basis of debt securities classified as available-for-sale, excluding primary categories. This represe...
Peer comparison
Commonly reported by insurers with large fixed-income portfolios.
Metric ID:
other_available_for_sale_debt_securities_amortized_cost_basisHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $4.32B | $6.60B | $8.43B | $9.97B | $9.99B | $8.72B | $10.32B | $10.28B | $12.54B | $12.84B | $12.64B | $14.21B | $14.52B | $14.89B | $14.34B | $13.26B | $13.98B | $15.43B | $15.62B | $15.52B |
| QoQ Change | — | +53.0% | +27.7% | +18.2% | +0.3% | -12.8% | +18.4% | -0.4% | +22.0% | +2.4% | -1.6% | +12.5% | +2.2% | +2.5% | -3.7% | -7.5% | +5.4% | +10.4% | +1.2% | -0.7% |
| YoY Change | — | — | — | — | +131.6% | +32.0% | +22.4% | +3.2% | +25.5% | +47.4% | +22.4% | +38.2% | +15.8% | +16.0% | +13.5% | -6.7% | -3.8% | +3.6% | +8.9% | +17.0% |
Range$4.32B – $15.62B
CAGR+30.9%
Avg YoY Growth+24.2%
Median YoY Growth+16.5%
Total at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's total?
- Regeneron Pharmaceuticals (REGN) reported total of $15.52B in Q1 2026.
- How has Regeneron Pharmaceuticals's total changed year-over-year?
- Regeneron Pharmaceuticals's total increased by 17.0% year-over-year, from $13.26B to $15.52B.
- What is the long-term trend for Regeneron Pharmaceuticals's total?
- Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's total has grown at a 33.7% compound annual growth rate (CAGR), from $3.65B to $15.62B.
- What does total mean?
- The original cost of debt investments held for sale, adjusted for accounting amortization.